{
  "symbol": "TLRY",
  "company": "Tilray Brands, Inc.",
  "generated_at": "2026-06-24T07:36:53.536Z",
  "event_count": 2,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-10T02:08:55.998Z",
      "summary": "Tilray is a multi-segment lifestyle consumer goods company anchored by medical/recreational cannabis but increasingly reliant on craft beverage assets (BrewDog, SweetWater, Breckenridge) following years of acquisitions. The June 9, 2026 8-K reveals a debt-for-equity exchange that reduced the convertible note burden by ~$6M while diluting shareholders — consistent with ongoing balance sheet management rather than strategic inflection. The company has executed a 1-for-10 reverse stock split (Dec 2, 2025) and is burning cash on an operating basis (-$52.7% margin). Revenue declined 7.8% YoY to $858M TTM. The stock is 77% below its 52-week high of $23.20 and trades far below all moving averages (MA200: $9.44). Cannabis rescheduling remains a theoretical catalyst but has failed to move the needle over many years — and the company's heavy Canada/EU revenue exposure limits direct U.S. legalization benefit. No insider open-market purchases in 90 days, only RSU vesting and one director sale. The options market shows elevated IV (0.98-1.00 for near-term ATM puts) but no whale positioning. Given persistent unprofitability, revenue decline, heavy dilution history, and a catalyst that has repeatedly failed to materialize, there is no compelling asymmetric setup here — either direction.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 20,
      "walltime_min": 37,
      "debug_path": "dossiers/2026-06-10-TLRY.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-27T20:08:52.937Z",
      "summary": "{\"symbol\":\"TLRY\",\"company\":\"Tilray Brands, Inc.\",\"investigation_summary\":\"Tilray is a small-cap cannabis-and-beverage conglomerate that has collapsed ~76% from its October 2025 high of $23.20 to $5.55 following a 1-for-10 reverse split and sustained revenue decline (-7.8% YoY). The company posted an EPS beat in May 2025 (+$0.20 vs. flat estimate) but then badly missed Q3 FY2026 (Feb) at -$0.02 vs.",
      "verdict": "unparseable",
      "tool_calls": 19,
      "walltime_min": 10,
      "debug_path": "dossiers/2026-05-27-TLRY.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "TLRY",
    "call": "SELL",
    "confidence": 3,
    "score": -5,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_strong_up": "+2 (43.7%)",
      "rsi_neutral": "0 (31.6)",
      "recent_macd_bearish_cross": "-2 (3d ago)",
      "broken_below_high": "-2 (-78.0% from high)"
    },
    "summary": "SELL (score -5) · 12-1 mom 43.7% · RSI 31.6 · below_both · -78.0% from high",
    "last_close": 4.61,
    "one_month_ago_close": 5.46,
    "twelve_month_ago_close": 3.8,
    "twelve_one_momentum_pct": 43.68,
    "rsi_14": 31.6,
    "ma_stack": "below_both",
    "from_period_high_pct": -78.05,
    "period_high": 21,
    "price_targets": {
      "bear": 6.5,
      "fair": 6.79,
      "bull": 24.15,
      "bear_return_pct": 41,
      "fair_return_pct": 47.4,
      "bull_return_pct": 423.9,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 6.5,
        "target_mean": 10.04444,
        "target_high": 24,
        "analyst_count": 9
      }
    },
    "generated_at": "2026-06-24T07:36:53.533Z"
  }
}